4D Molecular Therapeutics (FDMT) Total Current Liabilities (2019 - 2026)

4D Molecular Therapeutics (FDMT) has 8 years of Total Current Liabilities data on file, last reported at $43.4 million in Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $43.4 million, up 61.36% year-over-year; the trailing twelve-month figure through Mar 2026 was $43.4 million (up 61.36% YoY), and the FY2025 annual result was $44.0 million, up 50.9% from the prior year.
• Total Current Liabilities fell to $43.4 million in Q1 2026 per FDMT's latest filing, from $44.0 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $44.0 million in Q4 2025 and troughed at $11.3 million in Q1 2023.
• A 5-year average of $23.4 million and a median of $19.0 million in 2023 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2022 and 2025: Total Current Liabilities slipped 13.11% in 2022, then surged 78.72% in 2025.
• A 5-year view of Total Current Liabilities shows it stood at $15.7 million in 2022, then gained by 20.47% to $19.0 million in 2023, then surged by 53.81% to $29.1 million in 2024, then surged by 50.9% to $44.0 million in 2025, then declined by 1.32% to $43.4 million in 2026.
• Business Quant data shows FDMT's Total Current Liabilities at $43.4 million in Q1 2026, $44.0 million in Q4 2025, and $37.1 million in Q3 2025.